How is ResMed (RMD) doing?

ResMed is a company in the medical, instruments & supplies industry, based in San Diego, CA, worth $33.4B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Middling

ResMed shares are down 19% over the past year, 30 points behind the S&P 500. Its type is Turning Up. Among large US stocks and funds it ranks in the 17th percentile on market beat, the 44th on staying power and the 72nd on business growth. It appears on 5 of our dashboards, including 5th on “Who is spending big on expansion?”.

$230.05−19% in a yearWorth $33.4B

Compare with PODD · DXCM · INSP · MDT · BSX · GEHC · WST

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

RMD against the S&P 500, past year

$100 a year ago. ResMed −19%, the S&P 500 +16%.

RMDS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Turning Up

LaggingErraticGrowingBought

Lagging and erratic, but the business is growing and buyers are arriving.

NovDecJanFebMarAprMayJunJulAugSepNow

Turning Up this month; Show-Me Grower before that.

Also Turning Up (51 in all): EHC · ISRG · ZBH · MSA · PPG · SF

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

RMD, past year−19%72 of 86 in the group

Rest of the group+21%equal-weighted

S&P 500+16%past year

ResMed is −19% over the past year, against +21% for the rest of the group and +16% for the S&P 500. It ranks 72nd of 86 in Health care.

RMDRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsPODD Insulet−57%DXCM Dexcom+24%INSP Inspire Medical Systems−12%MDT Medtronic−10%BSX Boston Scientific−56%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual ResMed typically moves 2.4% in a day, about usual for it, and it swings less than 66% of large US stocks.

Typical day2.4%about $5.42 a share

Its usual2.7%about usual, 0.9× its year’s average

Against the S&P 5002.4×the index’s typical day is 1.1%

Unusual day±4.7%twice its typical day

Deepest fall, past year−35%now 19% below its high

In the S&P’s down weeks67%of the index’s fall, three years; beta 0.8

Typical daily move (ATR)Its year’s average 2.69%

RMD on our dashboards

Every question where ResMed appears, in the order of the home page, with its reading and place in that table. Select a question to open it with RMD highlighted. Select a column to sort.

Question	Reading	Place	Details
Which companies grow earnings every year? Business quality	93Long run	37 of 60	Years of growth 5 years · Growth, 5Y +26% a yr · Latest EPS 10.40
Which companies earn the most on their capital? Business quality	91Excellent	37 of 60	Return on capital 21% · Gross margin 62% · Cash margin 32%
Who is spending big on expansion? Business quality	99Ramping	5 of 60	Capex, 1Y +188% · A year $267.5M · % of revenue 5%
Which companies have more cash than debt? Value	92Net cash	30 of 60	Net cash $972.7M · % of value +3% · Debt payback 0.4 yrs
What are insiders buying? Who’s buying and selling	45Selling	49 of 60	Sold $1.1M · Who Chairman And CEO

Go deeper on Stox

RMD’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open RMD on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see RMD’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›PODD · Insulet ›DXCM · Dexcom ›INSP · Inspire Medical Systems ›MDT · Medtronic ›